PL1877098T3 - Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy - Google Patents
Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazyInfo
- Publication number
- PL1877098T3 PL1877098T3 PL06727008T PL06727008T PL1877098T3 PL 1877098 T3 PL1877098 T3 PL 1877098T3 PL 06727008 T PL06727008 T PL 06727008T PL 06727008 T PL06727008 T PL 06727008T PL 1877098 T3 PL1877098 T3 PL 1877098T3
- Authority
- PL
- Poland
- Prior art keywords
- carboxylesterase
- hydrolysable
- drug conjugates
- aminoacid ester
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0509226A GB0509226D0 (en) | 2005-05-05 | 2005-05-05 | Enzyme and receptor modulation |
US68054205P | 2005-05-13 | 2005-05-13 | |
PCT/GB2006/001635 WO2006117567A2 (en) | 2005-05-05 | 2006-05-04 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase |
EP06727008.2A EP1877098B1 (en) | 2005-05-05 | 2006-05-04 | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase |
Publications (1)
Publication Number | Publication Date |
---|---|
PL1877098T3 true PL1877098T3 (pl) | 2013-09-30 |
Family
ID=36609807
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL06727008T PL1877098T3 (pl) | 2005-05-05 | 2006-05-04 | Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy |
Country Status (11)
Country | Link |
---|---|
US (5) | US20090215800A1 (pl) |
EP (4) | EP3530290A1 (pl) |
JP (2) | JP2008542196A (pl) |
KR (1) | KR101332904B1 (pl) |
AU (1) | AU2006243000B2 (pl) |
BR (1) | BRPI0610368A8 (pl) |
CA (1) | CA2607020C (pl) |
IL (1) | IL186091A0 (pl) |
MX (1) | MX2007013257A (pl) |
PL (1) | PL1877098T3 (pl) |
WO (1) | WO2006117567A2 (pl) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
GB0608822D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of DHFR |
JP5340918B2 (ja) * | 2006-05-04 | 2013-11-13 | クロマ セラピューティクス リミテッド | p38MAPキナーゼ阻害剤 |
GB0608823D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of P13 kinase |
GB0608821D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | DHFR enzyme inhibitors |
GB0608837D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of MAP kinase |
GB0608854D0 (en) * | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | P13 kinase inhibitors |
GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
ES2509342T3 (es) | 2006-10-30 | 2014-10-17 | Chroma Therapeutics Limited | Hidroxamatos como inhibidores de histona desacetilasa |
GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
JP2011503042A (ja) * | 2007-11-07 | 2011-01-27 | クロマ セラピューティクス リミテッド | p38MAPキナーゼ阻害剤 |
EP2245012B1 (en) | 2008-02-29 | 2013-07-03 | Chroma Therapeutics Limited | Inhibitors of p38 map kinase |
GB0803747D0 (en) * | 2008-02-29 | 2008-04-09 | Martin | Enzyme and receptor modulation |
GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
WO2010144696A1 (en) | 2009-06-11 | 2010-12-16 | Burnham Institute For Medical Research | Directed differentiation of stem cells |
IN2012DN02534A (pl) | 2009-09-16 | 2015-08-28 | Avila Therapeutics Inc | |
BR112012015721A2 (pt) | 2009-12-30 | 2017-09-26 | Avila Therapeutics Inc | modificação covalente de proteínas dirigida por ligante |
GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
GB201211310D0 (en) | 2012-06-26 | 2012-08-08 | Chroma Therapeutics Ltd | CSF-1R kinase inhibitors |
CN104781235B (zh) | 2012-10-17 | 2016-12-21 | 色品疗法有限公司 | N-[2-{4-[6-氨基-5-(2,4-二氟苯甲酰)-2-氧代吡啶-1(2h)-基]-3,5-二氟苯基}乙基]-l-丙氨酸叔丁酯或其盐、水合物或溶剂合物 |
GB201504694D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
WO2017216297A1 (en) | 2016-06-16 | 2017-12-21 | Glaxosmithkline Intellectual Property Development Limited | Dosage regimen |
US10256877B2 (en) * | 2017-08-02 | 2019-04-09 | Qualcomm Incorporated | Apparatus and methods for beam refinement |
GB201713975D0 (en) | 2017-08-31 | 2017-10-18 | Macrophage Pharma Ltd | Medical use |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1345502A (en) | 1972-07-06 | 1974-01-30 | Parke Davis & Co | Quinazoline compounds and processes for their production |
US4725687A (en) * | 1986-04-28 | 1988-02-16 | Southern Research Institute | 5-methyl-5-deaza analogues of methotrexate and N10 -ethylaminopterin |
US5175153A (en) * | 1987-11-30 | 1992-12-29 | Warner-Lambert Company | Substituted alpha-amino acids having pharmaceutical activity |
US5331006A (en) * | 1990-08-31 | 1994-07-19 | Warner-Lambert Company | Amino acid analogs as CCK antagonists |
AU666416B2 (en) * | 1993-01-29 | 1996-02-08 | Tanabe Seiyaku Co., Ltd. | Ellipticine derivative and process for preparing the same |
US5480906A (en) * | 1994-07-01 | 1996-01-02 | Eli Lilly And Company | Stereochemical Wortmannin derivatives |
DE69622183D1 (de) | 1995-11-07 | 2002-08-08 | Kirin Brewery | Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen |
KR20010108481A (ko) * | 1999-04-09 | 2001-12-07 | 스타르크, 카르크 | 트롬빈 억제제의 프로드럭 |
US6448256B1 (en) * | 1999-05-24 | 2002-09-10 | University Of Massachusetts | Antibiotic prodrugs |
YU22402A (sh) * | 1999-09-08 | 2006-01-16 | Sloan-Kettering Institute For Cancer Research | Nova klasa agenasa za citodiferencijaciju i inhibitora histon deacetilaze, i postupci za njihovu upotrebu |
WO2002039997A2 (en) * | 2000-11-01 | 2002-05-23 | Millennium Pharmaceuticals, Inc. | Ace-2 modulating compounds and use thereof |
AU2003219889A1 (en) | 2002-02-22 | 2003-09-09 | Teva Pharmaceutical Industries Ltd. | Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide |
TWI314928B (en) * | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
US20040072735A1 (en) * | 2002-03-04 | 2004-04-15 | Richon Victoria M. | Methods of inducing terminal differentiation |
EP1487794A1 (en) | 2002-03-14 | 2004-12-22 | Bayer Aktiengesellschaft | Monocyclic aroylpyridinones as antiinflammatory agents |
BR0316206A (pt) * | 2002-11-12 | 2005-09-27 | Alcon Inc | Uso inibidores de histona desacetilase para o tratamento de distúrbios e de doenças oculares neovasculares ou edematosos |
NZ545570A (en) * | 2003-07-29 | 2012-07-27 | Signature R & D Holdings Llc | Amino acid prodrugs |
WO2005037272A1 (en) * | 2003-10-22 | 2005-04-28 | Arpida A/S | Benzimidazole derivatives and use thereof as peptide deformylase inhibitors |
WO2005072061A2 (en) * | 2004-02-02 | 2005-08-11 | Biosight Ltd. | Conjugates for cancer therapy and diagnosis |
TW200536528A (en) * | 2004-02-27 | 2005-11-16 | Schering Corp | Novel inhibitors of hepatitis C virus NS3 protease |
US8227636B2 (en) * | 2004-04-05 | 2012-07-24 | Merck Hdac Research, Llc | Histone deacetylase inhibitor prodrugs |
EP2261226B1 (en) * | 2004-05-14 | 2015-04-01 | Millennium Pharmaceuticals, Inc. | Methods for preparing aurora kinase inhibitors |
GB0509223D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
GB0509225D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
GB0509227D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Intracellular enzyme inhibitors |
GB0509224D0 (en) * | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of intracellular enzymatic activity |
GB0619753D0 (en) * | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
GB0621830D0 (en) * | 2006-11-02 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of p38 mitogen-activated protein kinase |
-
2006
- 2006-05-04 BR BRPI0610368A patent/BRPI0610368A8/pt not_active Application Discontinuation
- 2006-05-04 WO PCT/GB2006/001635 patent/WO2006117567A2/en not_active Application Discontinuation
- 2006-05-04 EP EP19156158.8A patent/EP3530290A1/en not_active Withdrawn
- 2006-05-04 KR KR1020077023742A patent/KR101332904B1/ko active IP Right Grant
- 2006-05-04 CA CA2607020A patent/CA2607020C/en active Active
- 2006-05-04 EP EP08075300.7A patent/EP1964577B1/en active Active
- 2006-05-04 EP EP06727008.2A patent/EP1877098B1/en active Active
- 2006-05-04 PL PL06727008T patent/PL1877098T3/pl unknown
- 2006-05-04 JP JP2008509506A patent/JP2008542196A/ja active Pending
- 2006-05-04 EP EP20080075301 patent/EP1964578A3/en not_active Ceased
- 2006-05-04 MX MX2007013257A patent/MX2007013257A/es active IP Right Grant
- 2006-05-04 US US11/918,138 patent/US20090215800A1/en not_active Abandoned
- 2006-05-04 AU AU2006243000A patent/AU2006243000B2/en not_active Ceased
-
2007
- 2007-09-20 IL IL186091A patent/IL186091A0/en unknown
-
2013
- 2013-07-02 JP JP2013139093A patent/JP2013241423A/ja active Pending
-
2014
- 2014-10-07 US US14/508,248 patent/US20150126534A1/en not_active Abandoned
-
2017
- 2017-07-14 US US15/650,031 patent/US20180000952A1/en not_active Abandoned
-
2019
- 2019-01-24 US US16/255,947 patent/US20190231887A1/en not_active Abandoned
-
2021
- 2021-05-21 US US17/326,470 patent/US20210361772A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2006243000A1 (en) | 2006-11-09 |
EP1964577B1 (en) | 2016-04-13 |
MX2007013257A (es) | 2008-01-21 |
BRPI0610368A2 (pt) | 2010-06-15 |
BRPI0610368A8 (pt) | 2015-09-08 |
CA2607020C (en) | 2015-01-13 |
EP3530290A1 (en) | 2019-08-28 |
EP1877098B1 (en) | 2013-04-24 |
IL186091A0 (en) | 2008-01-20 |
KR101332904B1 (ko) | 2013-11-26 |
AU2006243000B2 (en) | 2011-05-26 |
EP1877098A2 (en) | 2008-01-16 |
US20190231887A1 (en) | 2019-08-01 |
JP2008542196A (ja) | 2008-11-27 |
US20090215800A1 (en) | 2009-08-27 |
US20180000952A1 (en) | 2018-01-04 |
KR20080003809A (ko) | 2008-01-08 |
CA2607020A1 (en) | 2006-11-09 |
WO2006117567A3 (en) | 2007-08-30 |
EP1964577A3 (en) | 2008-11-05 |
US20210361772A1 (en) | 2021-11-25 |
EP1964577A2 (en) | 2008-09-03 |
US20150126534A1 (en) | 2015-05-07 |
EP1964578A3 (en) | 2008-11-05 |
JP2013241423A (ja) | 2013-12-05 |
EP1964578A2 (en) | 2008-09-03 |
WO2006117567A2 (en) | 2006-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2200002I1 (hu) | Immunogén készítmény | |
PL1877098T3 (pl) | Koniugaty estru alfa-aminokwasu z lekiem ulegające hydrolizie z udziałem karboksyloesterazy | |
GB0504436D0 (en) | Vaccine | |
HK1116776A1 (en) | Triazolophthalazines as pde2-inhibitors | |
ZA200709518B (en) | Vaccine composition | |
GB0526038D0 (en) | Immunogenic composition | |
GB0513069D0 (en) | Immunogenic composition | |
GB0515135D0 (en) | Vaccine | |
GB0516944D0 (en) | Vaccine | |
ZA200708283B (en) | Alpha aminoacid ester-drug conjugates hydrolysable by carboxylesterase | |
ZA200710854B (en) | Immunogenic composition | |
GB0502569D0 (en) | Vaccine composition | |
GB0524204D0 (en) | Immunogenic composition | |
GB0503143D0 (en) | Immunogenic composition | |
GB0503000D0 (en) | Anti-atheroma vaccine | |
GB0509010D0 (en) | Vaccine | |
GB0513191D0 (en) | Vaccine | |
GB0514021D0 (en) | Vaccine | |
GB0513189D0 (en) | Vaccine | |
GB0511475D0 (en) | Vaccine | |
GB0515242D0 (en) | Vaccine | |
GB0513194D0 (en) | Vaccine | |
GB0521164D0 (en) | Vaccine | |
GB0523445D0 (en) | Vaccine |